INTRODUCTION
Polypharmacy and potentially inappropriate medication (PIM) use are highly prevalent in older patients with cancer, and they are recognized as potential risk factors for adverse outcomes during cancer treatment. 1 Older adult patients with cancer are at high risk for PIM use because they receive not only medications to treat their medical comorbidities and malignancy but also medications to treat therapy-induced toxicity. [2] [3] [4] Furthermore, oncology patients are often seen by many different physicians and may receive medications for overlapping indications. 5, 6 The National Comprehensive Cancer Network's guidelines for senior adult oncology recommend a review of medications for appropriate use at every visit through screening tools validated in the general older adult population. 1 PIMs are medications or classes of drugs that have been deemed to have a high risk-to-benefit ratio and should thus be avoided in older persons. 7 Specific examples of classes deemed to be inappropriate include sedatives (eg, benzodiazepines) and anticholinergic drugs (eg, antispasmodics). The most commonly used measure of PIMs is the Beers criteria. 8 The Healthcare Effectiveness Data and Information Set (HEDIS) Drugs to Avoid in the Elderly (DAE) list includes the highest risk medications from the Beers list. 9, 10 Both have been developed through expert consensus. Among older adults in the general population, PIM use is predictive of significant morbidity, more adverse drug events, increased emergency department visits, increased hospitalization, and an increased risk of mortality. 7, [11] [12] [13] However, there is a dearth of evidence suggesting that these tools are applicable to the older adult cancer population receiving chemotherapy. 1 Several studies have found a high prevalence of PIM use in older cancer patients, with rates ranging from 21% to 40% and depending on the criteria used to define PIMs. The impact of PIM use on adverse outcomes has not been widely studied, but one study of older adults receiving chemotherapy found no association between PIM use and chemotherapy toxicity or hospitalizations. However, this population was heterogeneous and included patients with different cancer types and a high proportion with advanced disease. The purpose of this study was to evaluate the impact of PIM use on clinical outcomes in a population of patients with breast or colorectal cancer receiving adjuvant therapy. Our objective was to identify patient and disease characteristics associated with baseline PIM use (as defined by the Beers criteria and the DAE list) and the impact of baseline PIM use on health outcomes during adjuvant chemotherapy.
MATERIALS AND METHODS

Data Source
We used the merged Surveillance, Epidemiology, and End Results (SEER)-Medicare database as our data source. The SEER database is a population-based tumor registry sponsored by the National Cancer Institute that contains information on all newly diagnosed cancer cases occurring in persons residing in participating areas.
14 It includes approximately 28% of the US population and collects information on the following: patient demographics, tumor characteristics, stage, date of diagnosis, treatment, and date and cause of death. Medicare claims data are linked with SEER and include outpatient, inpatient, and physician claims. Part D Prescription Drug Events files include beneficiary identifiers that have been linked with Medicare claims files, and they include the drug name, fill date, National Drug Code number, quantity dispensed, number of days' supply, cost, and other plan-based variables. 14 
Study Population
This study included individuals diagnosed between July 1, 2007, and December 31, 2009, with American Joint Committee on Cancer stage II or III breast or colorectal cancer (modified third edition) who were 66 years old or older and had received adjuvant chemotherapy. 15 Identified individuals were required to have Medicare Part A and B coverage for a minimum of 12 months before and after their diagnosis and Part D coverage from 4 months before to 12 months after their diagnosis. Patients who were members of a health maintenance organization at any time during the 1 year before and after their diagnosis were excluded because of incomplete claims. Men with breast cancer were excluded.
Measures
We used the Current Procedural Terminology J codes in the SEER-Medicare Outpatient, Physician/Supplier, and Durable Medical Equipment files to identify adjuvant chemotherapy use. To be considered adjuvant chemotherapy, claims had to begin within 6 months of the diagnosis. The end date of active treatment was determined on the basis of the appearance of final J codes for chemotherapy, with no further treatment administered for at least a 90-day period. For breast cancer, regimens were classified as anthracycline-based if J codes for doxorubicin, epirubicin, or mitoxantrone were present. For colorectal cancer, regimens were determined to be multi-agent if they contained oxaliplatin-based J codes. Comorbid conditions present during the year before the diagnosis of cancer were determined with the International Classification of Diseases, Ninth Revision, diagnosis and procedure codes so that we could search the Medicare inpatient, outpatient, and physician claims data. The comorbidity score was calculated with Klabunde's adaptation of the Charlson Comorbidity Index from the macro provided by the National Cancer Institute. 16 Education and poverty were provided as census tract-level variables, and we identified the percentage of patients with <12 years of education or those living below the poverty line
Statistical Analysis
The first objective was to determine the prevalence of baseline PIM use and associated characteristics in older adult patients with breast or colorectal cancer receiving chemotherapy in the adjuvant setting. PIM use was defined on the basis of the 2012 Beers criteria and the DAE list. 10 Both tools have been used for retrospective application to administrative data. 9 The exposure period for detecting baseline PIMs ranged from 4 months before the diagnosis up to the date of diagnosis. Medications were included if patients received a single prescription for at least a 90 days' supply or a 30 days' supply prescription with more than 1 refill. Each of these tools resulted in a dichotomous measure of PIM usage (present or absent). PIM rates were also evaluated during the periods 0 to 3 months and 3 to 6 months after chemotherapy initiation.
Demographic variables included the patient age group, race/ethnicity, sex, and census tract-based education and poverty levels. Clinical variables included the year of diagnosis, stage, Charlson Comorbidity Index, baseline number of medications, baseline number of outpatient providers, and chemotherapy regimen PIM rates and other baseline sample characteristics were summarized for each cohort with descriptive statistics. Univariate and multivariate logistic regression was used to examine the association of study covariates with each PIM usage measure. Covariates associated with PIMs at the .2 significance level were candidates for the multivariate model, and those variables with P values < .05 were retained with the application of a backward model selection. Statistically and clinically significant variables were retained in the final model, with results expressed as odds ratios and 95% confidence intervals.
A second objective of the study was to determine whether baseline PIM use in older adults receiving chemotherapy was predictive of poor clinical outcomes: emergency room (ER) visits, hospitalization, death, and a composite of the 3 outcomes. We evaluated the 2 measures of PIM use (ie, the Beers criteria and the DAE list) separately. The time to event and event-free survival (EFS) were measured from the date of first chemotherapy to the date of the first outcome or the last follow-up if no outcome occurred (designated as 3 months after the last chemotherapy). Patients were right-censored at 3 months after the last chemotherapy. Hospitalization was defined as having 1 or more claims for a hospital stay and was found in Medicare Provider Analysis and Review files. ER visits were similarly defined and derived from Medicare Part B data files. Finally, mortality was considered to be death from any cause. The same independent variables used in the analysis of predictors of baseline PIM use were included in the analysis of adverse outcomes.
Cox proportional hazards models were fit to determine the association of patient and clinical characteristics with time-to-outcome endpoints, and the assumption was checked for the primary predictor (PIM use). Variables retained in the final model were based on both statistical and clinical significance. Results were expressed as hazard ratios and 95% confidence intervals. P values < .05 were considered to be statistically significant, and all tests were 2-sided. All statistical analyses were performed with SAS 9.3 (SAS Institute, Cary, North Carolina). This study was reviewed and approved by the institutional review board.
RESULTS
The final analysis included 1595 patients with breast cancer and 1528 patients with colorectal cancer. Baseline characteristics are shown in Table 1 . The frequency of baseline PIM use by the DAE list and the Beers criteria ranged from 15.5% to 27.6%. Except for the DAE list in the breast cancer cohort, at a time interval of 0 to 3 months after the initiation of chemotherapy, the frequency of PIM use in both cohorts was higher (Table 2) . In all cases, PIM use was lower at an interval 3 to 6 months after the initiation of chemotherapy. Table 3 shows the results of univariate and multivariate analyses of baseline PIM use. For the breast cancer cohort in the multivariate analysis, baseline PIM use by both criteria was associated with baseline use of 5 medications and younger age. In the colorectal cancer cohort, PIM use was associated with female sex and baseline use of 5 medications. There was an association with younger age and baseline PIM use by the DAE list and an association with non-Hispanic white race with the Beers criteria.
In the time-to-event analysis, the median follow-up for the breast cancer cohort was 5.7 months (range, 0-9 months; Table 4 ). The 1-year EFS rate for the composite outcome was 45% (95% confidence interval, 42%-48%). In the multivariate analysis, there was an association of an increased risk of ER visits with older age, advanced stage, higher comorbidity, baseline use of 5 medications, and baseline ER visits. An increased risk of hospitalization was associated with Hispanic race, advanced stage, higher comorbidity score, and baseline use of 5 medications. An increased risk of death was associated with older age, advanced stage, and baseline PIM use as defined by the DAE list. Finally, 37.5% of the patients experienced a composite outcome, and this was associated with advanced stage, higher comorbidity, baseline use of 5 medications, and higher numbers of ER visits or hospitalizations in the previous year. Baseline PIM usage, defined by the DAE list, was associated only with overall survival in the time-to-event analysis, and there were no other associations between baseline PIM use by either criteria and other outcomes (Table 5 ).
In the colorectal cancer cohort, the median followup was 5.9 months (range, 0-9 months) with a 1-year EFS rate of 38% (95% confidence interval, 35%-41%) for the composite outcome (Table 4 ). An increased risk of ER visits was associated with older age, female sex, higher comorbidity, non-Hispanic white race, baseline use of 5 medications, and baseline ER visits. An increased risk of hospitalization was associated with older age, female sex, non-Hispanic white race, and higher comorbidity. Death was associated with older age and higher comorbidity. Finally, 45% had a composite outcome, and this was associated with older age (76-80 vs 66-70 years), female sex, race (other vs non-Hispanic white), advanced stage (American Joint Committee on Cancer stage III vs II), higher comorbidity score (1 vs 0), the baseline number of medications (11 vs 0-4), and a history of ER visits/hospitalization in the prior year. Similarly to the breast cancer cohort, there was no association of baseline PIM use and any outcome (Table 6 ).
DISCUSSION
In this study, we found no association between baseline PIM use and adverse outcomes, including ER visits, hospitalizations, and death, in patients with breast or colorectal cancer receiving adjuvant chemotherapy. We did find that PIM use, ranging from 16% to 25% at the baseline according to the criteria applied, was prevalent and was associated with various patient characteristics. Our findings are consistent with those of Maggiore et al, 17 who noted a rate of PIM usage of up to 29% among cancer patients with the Beers criteria, and they did not find an association between PIM use and adverse outcomes. The rate of PIM use was less than that noted by Nightingale et al, 18 whose rates ranged from 21% to 40%.
Similarly to prior studies in the general geriatric population, a higher number of medications was associated with adverse outcomes in both the breast and colorectal cancer cohorts, and the implication is that polypharmacy is an important risk factor. In both groups, taking 5 medications at the baseline was associated with adverse outcomes. In the multivariate analysis, there was no association between baseline PIM use and most adverse clinical outcomes. The only association of significance in the time-to-event analysis was PIM use as defined by the DAE list and death in the breast cancer cohort. However, because of the inconsistency of these findings, no firm conclusions can be made. We expected to find an association between PIM use and adverse outcomes in older patients receiving chemotherapy. Maggiore et al's study 17 found no association between PIMs and outcomes, but the study population included 500 patients who were 65 years old or older, a majority (61%) of whom had advanced or metastatic disease. We focused our study on patients receiving adjuvant therapy, presumably with curative intent. We believed that in this group of patients it might be particularly important to optimize medication use and avoid PIMs and that in a population of patients with advanced disease, certain PIMs might be appropriately used in the provision of supportive care. However, unlike our study, Maggiore et al found no association between the number of medications and outcomes. They also evaluated other high-risk drug classes not considered PIMs (anticoagulants, antiplatelets, opioids, insulin, oral hypoglycemics, and antiarrhythmics) and found no association with outcomes. An advantage of Maggiore et al's study was that it was prospective and captured a large amount of patient-specific data. The limitation of their study was that the evaluation of polypharmacy and PIM use was cross-sectional and performed in a secondary analysis, with limited data on certain components of medication use (eg, dosage, frequency, and indication). As noted, some studies have shown a higher frequency of PIM usage. Nightingale et al 18 conducted a study of pharmacist-led medication assessment in 248 adults with a mean age of 80 years, 87% of whom had solid tumors; 16.3% had advanced-stage disease. In addition to capturing information on the number of medications (where polypharmacy was defined as 5 medications and excessive polypharmacy was defined as 10 medications), PIM use was categorized with the 2012 Beers criteria, the Screening Tool of Older Person's Prescriptions (STOPP) criteria, and the HEDIS DAE list. The mean number of mediations used was 9.23, with the prevalence of polypharmacy and excessive polypharmacy being 41% and 43%, respectively. The frequency of PIM use was noted to be 40% with the Beers criteria, 38% with the STOPP criteria, and 21% with the DAE list. The higher incidence of PIM use in this particular study was likely due to the fact that they were able to capture information on over-the-counter medications, such as nonsteroidal anti-inflammatory drugs and first-generation antihistamines.
Finally, in our study, we found that certain patient and disease characteristics were associated with PIM use. In both cohorts, the use of 5 medications at the baseline was associated with PIM use in the multivariate analysis. Interestingly, a younger age group (<80 years old) was also associated with PIM use. Finally, among the patients with colorectal cancer specifically, female sex was also associated with baseline PIM use. The association of polypharmacy and PIM use has been corroborated in several publications, including those by Nightingale et al 18 and Prithviraj et al. 19 Prithviraj et al found that patients taking 5 medications were significantly more likely to be prescribed a PIM as defined by the 2012 Beers criteria. The authors found that these patients were also likely to have a poorer functional status or have 5 comorbidities. Nightingale et al similarly found a significant association between the number of comorbidities and the Eastern Cooperative Oncology Group performance status. A factor unique to our analysis was the association of a younger age group with higher rates of PIM use at the baseline.
One major strength of our study was the inclusion of a large number of patients who were homogeneous with respect to their disease stage and treatment indication. However, the major limitation of our study was that it was retrospective and had the ability to include only a limited amount of data regarding patient and diseaserelated characteristics as well as medications. In addition, we captured only a cross-sectional assessment of PIM use. We did try to account for this by considering medications for which there was only a 90-day supply or multiple refills. Furthermore, Medicare Part D data do not include over-the-counter medications such as nonsteroidal antiinflammatory drugs and antihistamines, which have been captured in previous studies as prevalent medication classes considered PIMs.
The results of our study suggest that although polypharmacy was associated with adverse outcomes, PIMs were not associated with poor clinical outcomes in cancer patients receiving systemic therapy. It is possible that the patients did not actually continue to take PIMs once they were diagnosed with cancer and initiated chemotherapy. In addition, several supportive care medications that are considered PIMs may carry more benefit than harm for this select group of patients. Conversely, it may be that there are specific drugs or classes that carry the greatest risk and should be looked at with greater scrutiny. Furthermore, the more relevant outcome of PIM use in patients with cancer may be quality-of-life issues and financial toxicity, which are of greatest import in the context of advanced-stage disease. To determine this, more prospective studies are required that accurately capture polypharmacy, PIM use, and adherence to PIM agents in various patient and treatment settings. Baseline data in such studies should also include components of the geriatric assessment to control for confounding factors related to comorbidity and frailty that may account for discrepant outcomes. However, our findings call into question the attention that clinicians should invest in the screening of PIM use in our older adult patients with cancer. Concurrently, they also support an effort to reduce polypharmacy as a way of potentially reducing adverse outcomes. 
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